Efficacy, safety, and optimal intervention of belimumab for proliferative lupus nephritis patients in real-world settings: LOOPS registry

医学 狼疮性肾炎 贝里穆马布 内科学 干预(咨询) 重症监护医学 免疫学 疾病 B细胞激活因子 抗体 B细胞 精神科
作者
H. Sakai,Yusuke Miyazaki,Shingo Nakayamada,Satoshi Kubo,Kentaro Hanami,Shunsuke Fukuyo,Ayako Yamaguchi,Ippei Miyagawa,M Ueno,Hiroaki Tanaka,Yasuyuki Todoroki,Naoaki Ohkubo,Masashi Funada,Satsuki Matsunaga,Yoshiya Tanaka
出处
期刊:Rheumatology [Oxford University Press]
标识
DOI:10.1093/rheumatology/keae495
摘要

Abstract Objectives This study investigated the efficacy, safety and predictive factors of belimumab (BEL) in induction therapy for patients with proliferative lupus nephritis (LN) in real-world settings. Methods Patients with biopsy-proven ISN/RPS class III or IV LN, with or without coexisting class V LN, who underwent standard of care (SoC), glucocorticoid (GC) and either mycophenolate mofetil or cyclophosphamide treatments were included. Participants were treated with SoC (SoC group, n = 32) or BEL and SoC (BEL+SoC group, n = 30). The primary end point was complete renal response (CRR) at 52 weeks. Results Baseline patient characteristics were not significantly different between the two groups. The 52-week retention rate of BEL was 90.0%. The BEL+SoC group showed significantly higher CRR and primary efficacy renal response achievement at 52 weeks and significantly lower GC dosage, adverse events and Systemic Lupus International Collaborating Clinics damage index scores. Multivariate analysis of CRR achievement at 52 weeks revealed that the lack of estimated glomerular filtration rate (eGFR) improvement at 4 weeks was associated with CRR failure in the SoC group. A shorter duration (cut-off of 42 days) between the start of induction therapy and addition of BEL was also related to the CRR in the BEL+SoC group. Conclusion BEL, in addition to SoC, controls disease activity, reduces GC use and suppresses organ damage in case of proliferative LN. Earlier BEL induction within 6 weeks may help achieve CRR in treatment-resistant cases without eGFR improvement at 4 weeks after induction therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
英俊的铭应助qqq采纳,获得10
刚刚
Xw完成签到,获得积分10
1秒前
1秒前
量子星尘发布了新的文献求助10
2秒前
ChatGPT发布了新的文献求助10
2秒前
3秒前
3秒前
暴躁的嘉懿完成签到,获得积分10
5秒前
龙傲天完成签到 ,获得积分10
5秒前
hhh发布了新的文献求助10
6秒前
小杨完成签到,获得积分10
8秒前
风华正茂完成签到,获得积分10
9秒前
康康完成签到 ,获得积分10
11秒前
柒z完成签到,获得积分10
13秒前
赘婿应助momo采纳,获得10
17秒前
油点小鳄完成签到,获得积分20
20秒前
21秒前
21秒前
桐桐应助wish采纳,获得10
22秒前
23秒前
桐桐应助百十余采纳,获得10
26秒前
义气如萱发布了新的文献求助10
26秒前
26秒前
27秒前
小二郎应助KM比比采纳,获得10
28秒前
不能吃了发布了新的文献求助10
28秒前
李健的粉丝团团长应助LJJ采纳,获得10
29秒前
30秒前
31秒前
体贴绝音发布了新的文献求助10
31秒前
32秒前
丘比特应助sakegeda采纳,获得10
34秒前
35秒前
wish发布了新的文献求助10
35秒前
不能吃了完成签到,获得积分10
36秒前
36秒前
37秒前
39秒前
好滴捏发布了新的文献求助10
41秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173